RAS Leadership & Advisory Groups
Oversight
Oversight of the NCI RAS Initiative is carried out on a variety of levels. A leadership team within NCI administratively operates the program on the government side and interacts closely with the program’s leaders at the Frederick National Laboratory for Cancer Research (FNLCR) to develop program direction and evaluate progress. The Frederick National Lab Advisory Committee (FNLAC) was instrumental in approving the concept of the RAS Initiative and receives periodic updates from the Ad hoc RAS Working Group (see below). This Ad hoc group evaluates the scientific goals, direction, priorities, and progress of the hub projects at the FNLCR, as well as how the hub interfaces with industry and the extramural community.
National Cancer Institute RAS Leadership
NCI Director, Dr. W. Kimryn Rathmell
Christopher Kane, Ph.D.
Program Officer for National Missions, Contracting Officer Representative
Ed Harlow, Ph.D.
Special Assistant to the NCI Director
Frederick National Laboratory for Cancer Research RAS Leadership
Frank McCormick, Ph.D., F.R.S., DSc (Hon), RAS National Program Advisor, FNLCR and Professor, UCSF Helen Diller Family Comprehensive Cancer Center
Ethan Dmitrovsky, M.D.
Director, FNLCR
Dwight V. Nissley, Ph.D. Director of the Cancer Research Technology Program, FNLCR
RAS Initiative Advisory Groups
RAS Initiative Ad Hoc Working Group
The purpose of this working group is to provide the highest quality oversight to the technical aspects of the RAS Initiative and to provide findings and recommendations to the NFAC and the Ad hoc RAS Oversight Subcommittee.
Ad hoc RAS Working Group Chair
David A. Tuveson, M.D., Ph.D.
Roy J. Zuckerberg Professor
Director of the Cancer Center
Cold Spring Harbor Laboratory
Cold Spring Harbor, New York
Ad hoc RAS Working Group Members
Michelle Arkin, Ph.D.
Professor, Pharmaceutical Chemistry
Co-Director, Small Molecule Discovery Center
University of California, San Francisco
Gideon E. Bollag, Ph.D.
Chief Executive Officer
Plexxikon, Inc.
Berkeley, California
Christin E. Burd, Ph.D.
Assistant Professor, Cancer Biology and Genetics
Ohio State University Comprehensive Cancer Center
Channing J. Der, Ph.D.
Sarah Graham Kenan Distinguished Professor
Department of Pharmacology
UNC Lineberger Comprehensive Cancer Center
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
Nader Fotouhi, Ph.D.
Chief Scientific Officer
TB Alliance
New York, New York
Elizabeth M. Jaffee, M.D.
Deputy Director, The Sidney Kimmel Comprehensive Cancer Center
The Dana and Albert Cubby Broccoli Professor of Oncology
Co-Director, Skip Viragh Center for Pancreas Cancer
The Johns Hopkins University
Baltimore, Maryland
Robert D. Schreiber, Ph.D.
Alumni Endowed Professor of Pathology and Immunology
Professor of Molecular Microbiology
Director, Washington University Center for Human Immunology and Immunotherapy Programs
Program Co-Leader, Tumor Immunology
Siteman Comprehensive Cancer Center
Washington University School of Medicine
St. Louis, Missouri
Kevin M. Shannon, M.D.
Auerback Distinguished Professorship in Pediatric Molecular Oncology
Helen Diller Family Comprehensive Cancer Center
University of California, San Francisco
Roger K. Sunahara, Ph.D.
Professor of Pharmacology
Department of Pharmacology
University of California, San Diego
La Jolla, California
Matthew Vander Heiden, M.D., Ph.D.
Howard Hughes Medical Institute Faculty Scholar
Associate Professor of Biology
Koch Institute for Integrative Cancer Research
Massachusetts Institute of Technology
Cambridge, Massachusetts
Ex Officio
Candace S. Johnson, Ph.D.
President & CEO
M&T Bank Presidential Chair in Leadership
Roswell Park Comprehensive Cancer Center
Buffalo, New York
Christopher Kane, Ph.D.
Program Officer for National Missions
Contracting Officer Representative
National Cancer Institute
National Institutes of Health
Bethesda, Maryland